Committee holds SB 282 after hours of testimony on compounding ingredient sourcing and med‑spa oversight

A state public health committee spent most of its session taking detailed testimony on Senate Bill 282, a wide‑ranging measure that would tighten sourcing and testing requirements for compounding pharmacies and add registration and oversight provisions for medical spas. After more than a dozen witnesses — from patient advocates, pharmacists and clinicians to trade groups and compounding business owners — the committee agreed to hold the bill so the chair can draft revised amendment language.

Patient‑safety groups and some clinicians told the committee that unsafe or unauthorized active pharmaceutical ingredients (APIs) have been making their way into U.S. supply chains, sometimes marked for compounding even when produced at facilities not registered with the Food and Drug Administration. Shabir Imbursafdar of the Partnership for Safe Medicines said vendor validation is ‘‘common sense’’ and warned that unauthorized API shipments and inadequate third‑party quality testing risk making compounded products dangerous. "Just one unauthorized manufacturer in China last year over…